-
Oct 29, 2024 | 
onclive.com | Gregory J Riely |Benjamin Besse
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss unmet needs and future research directions in ALK-positive and ROS1-positive NSCLC. Clinicians referring a patient to MSK can do so by visiting msk.org/refer , emailing [email protected] , or by calling 833-315-2722
-
Oct 28, 2024 | 
onclive.com | Benjamin Besse |Gregory J Riely
Progression Patterns and Subsequent Therapies after Lorlatinib in ALK+ NSCLCGregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss progression patterns and therapies after lorlatinib in ALK-positive NSCLC. Clinicians referring a patient to MSK can do so by visiting msk.org/refer , emailing [email protected] , or by calling 833-315-2722
-
Oct 25, 2024 | 
onclive.com | Gregory J Riely |Benjamin Besse
Testing for ALK Fusions and ROS1 Rearrangements in NSCLCGregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss testing for ALK-positive and ROS1-positive non–small cell lung cancer. Clinicians referring a patient to MSK can do so by visiting msk.org/refer , emailing [email protected] , or by calling 833-315-2722
-
Oct 9, 2024 | 
nature.com | Ferdinandos Skoulidis |Ana Cobo |Meagan Montesion |Yi Yu |Natalie I. Vokes |Joseph Murray | +44 more
AbstractFor patients with advanced non-small-cell lung cancer (NSCLC), dual immune checkpoint blockade (ICB) with CTLA4 inhibitors and PD-1 or PD-L1 inhibitors (hereafter, PD-(L)1 inhibitors) is associated with higher rates of anti-tumour activity and immune-related toxicities, when compared with treatment with PD-(L)1 inhibitors alone. However, there are currently no validated biomarkers to identify which patients will benefit from dual ICB1,2.
-
Oct 4, 2024 | 
onclive.com | Benjamin Besse
CommentaryVideoOctober 4, 2024Author(s):Fact checked by:Benjamin Besse, MD, PhD, discusses mechanisms of resistance to amivantamab plus lazertinib vs osimertinib in patients with EGFR-mutant, advanced NSCLC.
-
Sep 30, 2024 | 
onclive.com | Benjamin Besse
The ARROS-1 Phase 1/2 study investigates the safety, tolerability, and efficacy of zidesamtinib (NVL-520), a ROS1-selective, brain-penetrant tyrosine kinase inhibitor, in heavily pre-treated patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) and other solid tumors, showing promising durable responses in both systemic and intracranial disease.
-
Sep 11, 2024 | 
onclive.com | Benjamin Besse
Benjamin Besse, MD, PhD, director, clinical research, and medical oncologist at Institute Gustave Roussy, discusses findings from the phase 3 CARMEN-LC03 trial (NCT04154956), which is examining tusamitamab ravtansine in patients with advanced nonsquamous non–small cell lung cancer (NSCLC).
-
Aug 9, 2024 | 
medscape.com | Benjamin Besse
closePlease confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Dr Besse takes us on the patient journey in the management of early stage cancer and poses some challenging questions on the use of ct-DNA (circulating tumor-DNA). Is it a prognostic factor? Can we select patients for escalation or de-escalation of therapy based on ct-DNA?
-
Feb 13, 2024 | 
nature.com | Benjamin Besse |Sylvia Hartl |Patrick M. Forde |Melissa Johnson |Dong-Wan Kim |Boaz E. Aronson | +7 more
AbstractFor patients with non-small-cell lung cancer (NSCLC) tumors without currently targetable molecular alterations, standard-of-care treatment is immunotherapy with anti-PD-(L)1 checkpoint inhibitors, alone or with platinum-doublet therapy. However, not all patients derive durable benefit and resistance to immune checkpoint blockade is common.
-
Jun 27, 2023 | 
targetedonc.com | Benjamin Besse
Benjamin Besse, MD, PhD, professor of medical oncology at Université Paris-Saclay and head of clinical research at Gustave Roussy, discusses the biomarker analysis of the phase 1/1b CHRYSALIS-2 (NCT04077463) study of amivantamab (Rybrevant) and lazertinib (Leclaza) in patients with EGFR-mutated non–small cell lung cancer (NSCLC). The trial enrolled patients who had previously received osimertinib (Tagrisso) for EGFR-mutated NSCLC.
